These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15451807)

  • 21. This is not Dr. Conn's aldosterone anymore.
    Brown NJ
    Trans Am Clin Climatol Assoc; 2011; 122():229-43. PubMed ID: 21686229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Aldosterone exacerbates chronic renal insufficiency].
    Kristensen KE; Egfjord M
    Ugeskr Laeger; 2011 Jan; 173(4):267-70. PubMed ID: 21262170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone and inflammation.
    Gilbert KC; Brown NJ
    Curr Opin Endocrinol Diabetes Obes; 2010 Jun; 17(3):199-204. PubMed ID: 20422780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
    Struthers AD; MacDonald TM
    Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?
    Ando H
    Hypertens Res; 2023 Apr; 46(4):1056-1057. PubMed ID: 36653520
    [No Abstract]   [Full Text] [Related]  

  • 26. Aldosterone: effects on the kidney and cardiovascular system.
    Briet M; Schiffrin EL
    Nat Rev Nephrol; 2010 May; 6(5):261-73. PubMed ID: 20234356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells.
    Mazak I; Fiebeler A; Muller DN; Park JK; Shagdarsuren E; Lindschau C; Dechend R; Viedt C; Pilz B; Haller H; Luft FC
    Circulation; 2004 Jun; 109(22):2792-800. PubMed ID: 15159288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells.
    Hatakeyama H; Miyamori I; Fujita T; Takeda Y; Takeda R; Yamamoto H
    J Biol Chem; 1994 Sep; 269(39):24316-20. PubMed ID: 7929089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldosterone as a mediator in cardiovascular injury.
    Stier CT; Chander PN; Rocha R
    Cardiol Rev; 2002; 10(2):97-107. PubMed ID: 11895576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
    Weinberger MH; Luft FC
    Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention.
    Bernal J; Pitta SR; Thatai D
    Am J Cardiovasc Drugs; 2006; 6(6):373-81. PubMed ID: 17192127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac aldosterone production in genetically hypertensive rats.
    Takeda Y; Yoneda T; Demura M; Miyamori I; Mabuchi H
    Hypertension; 2000 Oct; 36(4):495-500. PubMed ID: 11040225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling.
    Lijnen PJ; Petrov VV
    Methods Find Exp Clin Pharmacol; 2003 Sep; 25(7):541-64. PubMed ID: 14571285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
    Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
    J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats.
    Nakano S; Kobayashi N; Yoshida K; Ohno T; Matsuoka H
    Hypertens Res; 2005 Nov; 28(11):925-36. PubMed ID: 16555582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?
    Bender SB; McGraw AP; Jaffe IZ; Sowers JR
    Diabetes; 2013 Feb; 62(2):313-9. PubMed ID: 23349535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
    Sato A; Saruta T; Funder JW
    Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
    Black HR
    Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Endothelial dysfunction and angiotensin-converting enzyme inhibitors in coronary disease].
    Mélon P
    Rev Med Liege; 1998 Jun; 53(6):353-4. PubMed ID: 9713215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.